Enterprise League logo
ERYTECH Pharma Logo

ERYTECH Pharma

UNVERIFIED COMPANY

You are in a "view as others" mode

Overview

Clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Description

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).

Founded 2004

50-100

Products

Looks like ERYTECH Pharma has no published products yet.

Services

Looks like ERYTECH Pharma has no published services yet.

Company reviews

This company reviews are private
Profile Strength:

undefined%

profile
completion

Add your telephone number
Contact details

contact@erytech.com

Lyon, France